Our Services
Medical Information
Helpful Resources
Published on: 8/18/2026
Adult bones can soften when a genetic shortage of the enzyme alkaline phosphatase disrupts mineralization, a condition called hypophosphatasia (HPP). Because mineral never fully deposits into the bone matrix, adults may develop osteomalacia with aching thighs or hips, stress fractures in the feet, early tooth loss, joint pain from calcium crystal deposits, and fatigue that gets dismissed as aging. Blood work often shows low alkaline phosphatase alongside elevated vitamin B6 or urinary phosphoethanolamine, and genetic testing of the ALPL gene can confirm it. Standard osteoporosis drugs such as bisphosphonates may worsen HPP, so an accurate diagnosis changes treatment entirely, with enzyme replacement therapy available for some patients. Several important factors affect how HPP presents and is managed, so review the complete details below before drawing conclusions.
If you're worried about unexplained bone pain, recurring fractures, or dental problems, a free, instant symptom check can help you organize your symptoms and understand which specialists and tests may be most relevant to your situation.
Last reviewed for medical accuracy: 08/18/2026
Bones give our body structure, protect organs, and enable movement. When our skeleton is healthy, bones stay strong and rigid. However, in some adults, bones can soften—a condition often linked to hypophosphatasia (HPP disease). This guide explains why bones soften in adults with HPP, what to watch for, and how to move forward.
Hypophosphatasia (HPP) is a rare genetic disorder affecting an enzyme called alkaline phosphatase (ALP). This enzyme plays a key role in bone mineralization—the process of laying down calcium and phosphate to harden bone. When ALP activity is low, minerals don’t bind properly, and bones remain soft or become weak.
Key points about HPP disease:
In adult HPP, reduced ALP activity leads to:
Other factors that may contribute to bone softening in adults:
Adults with HPP can experience a variety of signs. Not everyone will have every symptom, and severity varies.
Typical features include:
Less common or supportive signs:
Diagnosing HPP disease involves a combination of clinical evaluation, lab tests, imaging, and sometimes genetic studies.
Clinical Evaluation
Laboratory Tests
Imaging
Genetic Testing
There’s no one-size-fits-all cure for HPP, but several strategies can help manage symptoms and strengthen bones.
Regular check-ups are essential to track progress and adjust treatment:
Recognize Symptoms Early
If you have unexplained bone pain, frequent fractures, or dental issues, consider HPP as a possibility.
Get a Professional Opinion
Speak to a specialist in metabolic bone diseases or an endocrinologist.
Do an Online Symptom Check
For a quick, doctor-approved overview of your symptoms, you might consider doing a free, online symptom check, using the doctor approved Ubie Symptom Checker.
Arrange Lab Tests
Ask your healthcare provider for serum ALP and related blood tests.
Explore Treatment Options
Discuss enzyme replacement therapy, nutrition, and lifestyle changes with your doctor.
Some symptoms can signal serious complications. Contact a healthcare professional right away if you experience:
If you’re ever in doubt about the seriousness of your condition, speak to a doctor immediately.
While HPP can present challenges, many adults lead full, active lives with proper management. Key tips:
Above all, open communication with your healthcare team ensures you get timely interventions and support. Remember that early recognition and consistent care make a significant difference in bone health and quality of life.
If you notice any worrying signs or suspect HPP disease, speak to a doctor about your concerns. Prompt attention and tailored treatment can help you maintain stronger bones and better overall health.
(References)
* Inoue M. [Hypophosphatasia]. Nihon Rinsho. 2006 Jun 28;Suppl 2:104-7. PMID: 16817361.
* Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, Dahir KM, Nunes ME. Hypophosphatasia. GeneReviews(®). 1993. PMID: 20301329.
* Rockman-Greenberg C. Hypophosphatasia. Pediatr Endocrinol Rev. 2013 Jun;10 Suppl 2:380-8. PMID: 23858621.
* Feingold KR, Adler RA, Ahmed SF, Anawalt B, Blackman MR, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hamilton E, Hofland J, Jan de Beur S, Kalra S, Kaltsas G, Kapoor N, Kim M, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Sperling MA, Stratakis CA, Trence DL, Wilson DP, Lewiecki EM. Osteoporosis: Clinical Evaluation. Endotext. 2000. PMID: 25905277.
* Whyte MP. Hypophosphatasia - aetiology, nosology, pathogenesis, diagnosis and treatment. Nat Rev Endocrinol. 2016 Apr;12(4):233-46. doi: 10.1038/nrendo.2016.14. Epub 2016 Feb 19. PMID: 26893260.
* Riancho JA. Diagnostic Approach to Patients with Low Serum Alkaline Phosphatase. Calcif Tissue Int. 2023 Mar;112(3):289-296. doi: 10.1007/s00223-022-01039-y. Epub 2022 Nov 8. PMID: 36348061.
* Cianferotti L. Osteomalacia Is Not a Single Disease. Int J Mol Sci. 2022 Nov 28;23(23). doi: 10.3390/ijms232314896. Epub 2022 Nov 28. PMID: 36499221; PMCID: PMC9740398.
* Schini M, Vilaca T, Gossiel F, Salam S, Eastell R. Bone Turnover Markers: Basic Biology to Clinical Applications. Endocr Rev. 2023 May 8;44(3):417-473. doi: 10.1210/endrev/bnac031. PMID: 36510335; PMCID: PMC10166271.
* Rush E, Brandi ML, Khan A, Ali DS, Al-Alwani H, Almonaei K, Alsarraf F, Bacrot S, Dahir KM, Dandurand K, Deal C, Ferrari SL, Giusti F, Guyatt G, Hatcher E, Ing SW, Javaid MK, Khan S, Kocijan R, Lewiecki EM, Linglart A, M'Hiri I, Marini F, Nunes ME, Rockman-Greenberg C, Roux C, Seefried L, Starling SR, Ward L, Yao L, Brignardello-Petersen R, Simmons JH. Proposed diagnostic criteria for the diagnosis of hypophosphatasia in children and adolescents: results from the HPP International Working Group. Osteoporos Int. 2024 Jan;35(1):1-10. doi: 10.1007/s00198-023-06843-2. Epub 2023 Nov 20. PMID: 37982855; PMCID: PMC10786745.
* Magagnoli J, Knopf K, Hrushesky WJ, Carson KR, Bennett CL. Ferric Carboxymaltose (FCM)-Associated Hypophosphatemia (HPP): A Systematic Review. Am J Hematol. 2025 May;100(5):840-846. doi: 10.1002/ajh.27598. Epub 2025 Feb 11. PMID: 39935027; PMCID: PMC11966349.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.